Most patients with rheumatoid arthritis (RA) will undergo orthopaedic surgery during the course of their disease, and more than 80% of that cohort will be taking traditional or biologic disease-modifying antirheumatic drugs (DMARDs) at the time of their operations. 170 more words
Tags » Tocilizumab
A relatively new biologic treatment that is approved for treating rheumatoid arthritis is Tocilizumab (trade name Actemra and RoActemra). Tocilizumab is a humanised monoclonal antibody that targets interleukin-6 receptor (IL-6R), thus blocking interleukin-6 (IL-6) cytokine mediated signalling, which is known to play an important role in mediating inflammatory processes. 242 more words
MADRID, Spain — Children with polyarticular juvenile idiopathic arthritis treated with tocilizumab (Actemra, Genentech) achieved high response rates with sustained improvement in the phase 3 CHERISH trial. 127 more words
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.
April 30, 2013
Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra (tocilizumab) for the treatment of polyarticular juvenile idiopathic arthritis (PJIA). 780 more words
Newzealand's PHARMAC is seeking feedback on a proposal to list pegfilgrastim (Neulastim) and tocilizumab (Actemra) , from 1 July 2013, with Roche Products (NZ) Limited.
Tocilizumab and pegfilgrastim
12 April 2013
PHARMAC is seeking feedback on a proposal to list pegfilgrastim (Neulastim) for prevention of neutropenia in patients undergoing cancer chemotherapy, and tocilizumab (Actemra) for systemic juvenile idiopathic arthritis, from 1 July 2013, through a provisional agreement with Roche Products (NZ) Limited. 290 more words